Research·October 24, 2026 at 10:30 AM EDT·2 sources
Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
AMGN -1.8%AZN
AMGN · last 30 trading days-1.8% since the news
News
Median survival with combination21.1 months
Median survival with Imfinzi alone12.7 months
What happened
- Amgen said adding Imdelltra to AstraZeneca’s Imfinzi cut the risk of death by 58% in extensive-stage small cell lung cancer.
- Median overall survival was 21.1 months with the combination versus 12.7 months with Imfinzi alone.
- The Phase 3 trial tested the combination as first-line maintenance therapy after initial Imfinzi and chemotherapy, when cancer had not progressed.
Reduction in risk of death
58%
Median survival with combination
21.1 months
Median survival with Imfinzi alone
12.7 months
Imdelltra second-quarter sales
$288 million
Why it matters
The results could expand Imdelltra’s use from later-line treatment into first-line maintenance, with implications for Amgen’s commercial outlook and AstraZeneca’s lung-cancer regimen.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- EarlierOct 23Roche taps Zymeworks in up to $813M deal for preclinical T cell engager
- First reported by CNBCYesterdayAmgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
- Endpoints News reportsYesterday#ESMO26: Amgen's Imdelltra regimen more than halves risk of death in Phase 3 lung cancer trial
Who is involved
Amgen says drug combo cuts risk of death by 58% in patients w…AmgenAMGNAstraZenecaAZNImdelltraImfinziPaul BurtonJacob Sands
CompanyPerson
Sources (2)
Related
- 2h · STAT+: At ESMO, AstraZeneca’s cancer pursuits get a showcase
- 4h · #ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trial
- 4h · #ESMO26: AstraZeneca's Tagrisso-Orpathys combo may extend Tagrisso's life in lung cancer
- 4h · Roche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study
- Yesterday · #ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
- Oct 23 · Roche taps Zymeworks in up to $813M deal for preclinical T cell engager
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.